Vapotherm, Inc. announced the presentation of an Investigator-initiated clinical trial, ?High flow humidified oxygen as an early intervention in children with acute severe asthma - a feasibility.
Vapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients.
Vapotherm, Inc. (NYSE:VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of
Vapotherm Inc (NASDAQ: VAPO) announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an early intervention